February 15, 2018 / 6:14 AM / in 6 months

BRIEF-Santhera Says Obtains Worldwide Exclusive License From Polyphor

Feb 15 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG :

* SANTHERA OBTAINS WORLDWIDE EXCLUSIVE LICENSE FROM POLYPHOR TO DEVELOP AND COMMERCIALIZE CLINICAL STAGE CANDIDATE FOR CYSTIC FIBROSIS AND OTHER PULMONARY DISEASES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below